Effectiveness, Safety, Adherence, and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir/ Emtricitabine/Tenofovir Alafenamide

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The primary objective of this study is to evaluate HIV-1 RNA suppression, defined as HIV-1 RNA \<50 copies/mL, at 12 months after initiating or switching to Bictegravir/ Emtricitabine/Tenofovir alafenamide (B/F/TAF).
Epistemonikos ID: 4ebba2ef04000d13bcdf9dfe61c39f3646726f06
First added on: May 21, 2024